New PET imaging tracer for liver cancer
Part of Cancer, Digestive system clinical trials.
This study tests a new imaging tracer to better see liver cancer on PET scans, which might help doctors find or monitor tumors more accurately.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must be able to understand and sign the consent form.
- You need a diagnosis or suspicion of hepatocellular carcinoma, or a confirmed diagnosis with no prior systemic treatment, or a suspected recurrence after previous treatment.
- You must have had a standard FDG PET/CT scan for staging or restaging.
- You cannot have severe unrelated illnesses, be pregnant or breastfeeding, or be unable to cooperate with the scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new imaging technique that may help doctors see liver cancer more clearly. It uses a special tracer that targets a protein found on many liver cancer cells. This could help with diagnosis and monitoring.
This trial uses a special PET scan (68Ga-FAPI) to see how well systemic therapy is working in people with advanced liver cancer that can't be removed by surgery. The goal is to find a better way to measure treatment effectiveness.
This trial tests a new PET imaging method that uses two different tracers to find and stage liver cancer (HCC) or neuroendocrine tumors (GEP-NET) more accurately. It may help doctors decide on the best treatment for you.
This trial uses a special PET scan tracer (zirconium-labelled girentuximab) to see if it can find and track certain liver, bile duct, and pancreatic/intestinal neuroendocrine tumors. It may help doctors better understand your cancer and guide treatment decisions.
This study tests a new imaging agent that helps PET scans show cancer more clearly. It may help doctors see where cancer is in your body and plan your treatment better.
This trial tests a new imaging agent that may help doctors see tumors more clearly during a PET scan. It is for people with certain types of cancer who are willing to have a biopsy of their tumor.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.